Product Name :
CITCO
Description:
CITCO, an imidazothiazole derivative, is a selective Constitutive androstane receptor (CAR) agonist. CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49 nM over pregnane X receptor (PXR), and no activity on other nuclear receptors.
CAS:
338404-52-7
Molecular Weight:
436.74
Formula:
C19H12Cl3N3OS
Chemical Name:
(E)-[6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methylidene[(3,4-dichlorophenyl)methoxy]amine
Smiles :
ClC1C=CC(=CC=1)C1N=C2SC=CN2C=1/C=N/OCC1=CC(Cl)=C(Cl)C=C1
InChiKey:
ZQWBOKJVVYNKTL-AUEPDCJTSA-N
InChi :
InChI=1S/C19H12Cl3N3OS/c20-14-4-2-13(3-5-14)18-17(25-7-8-27-19(25)24-18)10-23-26-11-12-1-6-15(21)16(22)9-12/h1-10H,11H2/b23-10+
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
CITCO, an imidazothiazole derivative, is a selective Constitutive androstane receptor (CAR) agonist. CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49 nM over pregnane X receptor (PXR), and no activity on other nuclear receptors.|Product information|CAS Number: 338404-52-7|Molecular Weight: 436.74|Formula: C19H12Cl3N3OS|Chemical Name: (E)-[6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methylidene[(3,4-dichlorophenyl)methoxy]amine|Smiles: ClC1C=CC(=CC=1)C1N=C2SC=CN2C=1/C=N/OCC1=CC(Cl)=C(Cl)C=C1|InChiKey: ZQWBOKJVVYNKTL-AUEPDCJTSA-N|InChi: InChI=1S/C19H12Cl3N3OS/c20-14-4-2-13(3-5-14)18-17(25-7-8-27-19(25)24-18)10-23-26-11-12-1-6-15(21)16(22)9-12/h1-10H,11H2/b23-10+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 25 mg/mL (57.Nilotinib MedChemExpress 24 mM; Need ultrasonic).Nivolumab Immunology/Inflammation |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:32228336 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|CITCO (1-50 μM; 48 hours) results in a dose-dependent inhibition of viable cell count and proliferation in both T98G and U87MG glioma and BTSCs. CITCO (2.5, 5 μM; 48 hours) induces cell cycle arrest differentially in different BTSCs in culture, but not in normal astrocytes. CITCO (2.5-10 μM; 48 hours) induces apoptosis in BTSCs in culture in dose dependently, but not in normal astrocytes. CITCO (0-25 μM; 48 hours) causes the T98G and U87MG glioma and BTSCs expressing very low levels of CAR protein that increased significantly.|In Vivo:|CITCO (intraperitoneal; on days 22, 24, 26, 30 and 36) with 25 μg results a significant decrease in tumour growth, which further decreases to an undetectable level after treatment with 100 μg CITCO .|Products are for research use only. Not for human use.|